Intellia Therapeutics NTLA EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Intellia Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Intellia Therapeutics's EBITDA margin?
- Intellia Therapeutics (NTLA) reported EBITDA margin of -622.2% in Q1 2026.
- How has Intellia Therapeutics's EBITDA margin changed year-over-year?
- Intellia Therapeutics's EBITDA margin increased by 46.6% year-over-year, from -1,164.8% to -622.2%.
- What is the long-term trend for Intellia Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), Intellia Therapeutics's EBITDA margin has grown at a 23.2% compound annual growth rate (CAGR), from -224.6% to -637.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.